keyword
MENU ▼
Read by QxMD icon Read
search

LDV

keyword
https://www.readbyqxmd.com/read/28108232/ns5a-resistance-associated-substitutions-in-patients-with-genotype-1-hepatitis-c-virus-prevalence-and-effect-on-treatment-outcome
#1
Stefan Zeuzem, Masashi Mizokami, Stephen Pianko, Alessandra Mangia, Kwang-Hyub Han, Ross Martin, Evguenia Svarovskaia, Hadas Dvory-Sobol, Brian Doehle, Charlotte Hedskog, Chohee Yun, Diana M Brainard, Steven Knox, John G McHutchison, Michael D Miller, Hongmei Mo, Wan-Long Chuang, Ira Jacobson, Gregory J Dore, Mark Sulkowski
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs). We analyzed data from 35 phase 1, 2, and 3 studies in 22 countries to determine the pretreatment prevalence of various NS5A RASs, and their effect on outcomes of treatment with ledipasvir-sofosbuvir in patients with genotype 1 HCV. METHODS: NS5A gene deep sequencing analysis was performed on samples from 5,397 patients in Gilead clinical trials...
January 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28079680/middle-ear-sound-transmission-under-normal-damaged-repaired-and-reconstructed-conditions
#2
Wei Dong, Ying Tian, Xin Gao, Timothy T K Jung
HYPOTHESIS: We hypothesize that current clinical treatment strategies for the disarticulated or eroded incus have the effect of combining the incus and stapes of the human middle ear (ME) into one rigid structure, which, while capable of adequately transmitting lower-frequency sounds, fails for higher frequencies. BACKGROUND: ME damage causes conductive hearing loss (CHL) and while great progress has been made in repairing or reconstructing damaged MEs, the outcomes are often far from ideal...
January 10, 2017: Otology & Neurotology
https://www.readbyqxmd.com/read/28078723/real-world-use-effectiveness-and-safety-of-anti-viral-treatment-in-chronic-hepatitis-c-genotype-3-infection
#3
M Cornberg, J Petersen, A Schober, S Mauss, K H W Böker, R Link, R Günther, Y Serfert, H Pfeiffer-Vornkahl, M P Manns, C Sarrazin, D Hüppe, T Berg, C Niederau
BACKGROUND: Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited data. AIM: To validate the use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection under real-word conditions. METHODS: The German Hepatitis C-Registry is a large national non-interventional real-world study for patients with chronic hepatitis C...
January 12, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28078644/eight-or-12-week-treatment-of-hepatitis-c-with-ledipasvir-sofosbuvir-real-world-experience-in-a-large-integrated-health-system
#4
Jennifer B Lai, Maxwell A Witt, Mary Patricia Pauly, Joanna Ready, Michael Allerton, Suk Seo, David J Witt
BACKGROUND: Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use. Controversy exists regarding applicability of clinical trials to real-world effectiveness. We report virologic responses of patients with HCV genotype 1 infection receiving LDV/SOF for 8 or 12 weeks in a large integrated healthcare system...
January 11, 2017: Drugs
https://www.readbyqxmd.com/read/28070175/a-special-meeting-review-edition-advances-in-the-treatment-of-hepatitis-c-virus-infection-from-the-2016-easl-meeting-the-annual-meeting-of-the-european-association-for-the-study-of-the-liver-%C3%A2-april-13-17-2016-%C3%A2-barcelona-spainspecial-reporting-on-%C3%A2-six-weeks
#5
https://www.readbyqxmd.com/read/28059297/absolute-distance-measurement-system-with-micron-grade-measurement-uncertainty-and-24-m-range-using-frequency-scanning-interferometry-with-compensation-of-environmental-vibration
#6
Cheng Lu, Guodong Liu, Bingguo Liu, Fengdong Chen, Yu Gan
We establish a theoretical model of the Doppler effect in absolute distance measurements using frequency scanning interferometry (FSI) and propose a novel FSI absolute distance measurement system. This system incorporates a basic FSI system and a laser Doppler velocimeter (LDV). The LDV results are used to correct for the Doppler effect in the absolute distance measurement signal obtained by the basic FSI system. In the measurement of a target located at 16 m, a measurement resolution of 65.5 μm is obtained, which is close to the theoretical resolution, and a standard deviation of 3...
December 26, 2016: Optics Express
https://www.readbyqxmd.com/read/28059254/nonmechanical-scanning-laser-doppler-velocimetry-for-distribution-measurements-of-two-dimensional-velocity-vectors-based-on-optical-quadrature-detection
#7
Koichi Maru
This paper proposes a nonmechanical scanning laser Doppler velocimeter (LDV) for measuring the distribution of two-dimensional velocity vectors. In the proposed LDV, an optical quadrature detection technique and a nonmechanical axial scanning technique are introduced into a reference-type LDV. Consequently, the LDV has a simple optical system without multiple light sources or frequency shifting and does not have any moving mechanisms in the probe. The experimental results obtained using a sensor probe setup indicate that the function of measuring two-dimensional velocity vectors and the scanning function are successfully demonstrated...
December 20, 2016: Applied Optics
https://www.readbyqxmd.com/read/28052633/hepatitis-c-efficacy-and-safety-in-real-life
#8
REVIEW
Robert Flisiak, Joanna Pogorzelska, Marta Flisiak-Jackiewicz
Interferon-free combinations were registered in 2014 and 2015 for the treatment of chronic HCV infection. As a result, real-world experience has been gathered in the last year and this paper presents data available in September 2016. Real-world studies on the efficacy of the ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen showed a sustained virologic response (SVR) rate of between 91% and 98%. The SVR rate in the 13858 patients included in this paper was 94%, and 92% in the 3506 patients with cirrhosis...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28050236/hepatitis-c-eradication-with-sofosbuvir-leads-to-significant-metabolic-changes
#9
Amilcar L Morales, Zachary Junga, Manish B Singla, Maria Sjogren, Dawn Torres
AIM: To assess the effect of sofosbuvir (SOF) based regimens on glycemic and lipid control. METHODS: This is a retrospective analysis of hepatitis C virus (HCV)-infected patients treated and cured with a SOF regimen [SOF/ribavirin/interferon, SOF/simeprevir, or SOF/ledipasvir (LDV) ± ribavirin] from January 2014 to March 2015. Patients with hemoglobin A1C (HbA1C) and lipid panels within six months before and six months after therapy were identified and included in our study...
December 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/28046099/cost-effectiveness-of-treating-hepatitis-c-with-sofosbuvir-ledipasvir-in-germany
#10
Jona T Stahmeyer, Siegbert Rossol, Sebastian Liersch, Ines Guerra, Christian Krauth
BACKGROUND: Infections with the hepatitis C virus (HCV) are a global public health problem. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Newly introduced direct acting antivirals, especially interferon-free regimens, have improved rates of sustained viral response above 90% in most patient groups and allow treating patients who were ineligible for treatment in the past. These new regimens have replaced former treatment and are recommended by current guidelines...
2017: PloS One
https://www.readbyqxmd.com/read/28040553/efficacy-and-safety-of-ledipasvir-sofosbuvir-with-and-without-ribavirin-in-patients-with-chronic-hepatitis-c-virus-genotype-1-infection-a-meta-analysis
#11
Tingting Tao, Xuehua Jiang, Yuehong Chen, Yiran Song
BACKGROUND: The addition of ribavirin (RBV) to the combination treatment of Ledipasvir (LDV) and Sofosbuvir (SOF) remains controversial in the treatment of hepatitis C virus (HCV) infection. We performed a meta-analysis to assess the efficacy and safety of the LDV-SOF with and without RBV in treating HCV genotype 1 patients. METHOD: The electronical databases of PubMed Medline, EMBASE database, Cochrane Central Register of Controlled Trial (CENTRAL) and ClinicalTrials...
December 28, 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28027579/eight-weeks-of-ledipasvir-sofosbuvir-is-effective-for-selected-patients-with-genotype-1-hepatitis-c-virus-infection
#12
Kris V Kowdley, Vinay Sundaram, Christie Y Jeon, Kamran Qureshi, Nyan L Latt, Amandeep Sahota, Stephen Lott, Michael P Curry, Naoki Tsai, Nathorn Chaiyakunapruk, Yoori Lee, Jorg Petersen, Peter Buggisch
: Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus (HCV) infected patients who are treatment naive, non-cirrhotic and have pre-treatment viral load < 6 million IU/ml. The effectiveness of this regimen, however, has not been fully confirmed by real-world experience. Using data from real-world cohorts, we aimed to determine the effectiveness of 8 weeks of LDV/SOF treatment, examine variables associated with relapse after treatment with this regimen, and compare the effectiveness of 8 weeks and 12 weeks of LDV/SOF treatment...
December 27, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28024609/mesenchymal-stem-cell-laden-hybrid-scaffold-for-regenerating-subacute-tympanic-membrane-perforation
#13
Chul Ho Jang, SeungHyun Ahn, Jae Whi Lee, Byeong Ha Lee, Hyeongjin Lee, GeunHyung Kim
Tympanic membrane (TM) perforation is one of the most common otology complications. To date, there has not been reported TM regeneration using bioprinted scaffold. The purpose of this study was to evaluate the efficacy and feasibility of bioprinted polycaprolactone/collagen/alginate-mesenchymal stem cell (PCAMSC) scaffolds for the regeneration of subacute TM perforation. Sprague-Dawley rats were used in an animal model of subacute TM perforation. In the experimental group (n=7), bioprinted 3D PCAMSC scaffold was placed on the perforation...
March 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/27996239/cancer-cell-specific-delivery-of-photosystem-i-through-integrin-targeted-liposome-shows-significant-anticancer-activity
#14
Abhijit Saha, Saswat Mohapatra, Gaurav Das, Batakrishna Jana, Subhajit Ghosh, Debmalya Bhunia, Surajit Ghosh
Many anticancer drugs are developed for the treatment of cancer from natural sources. Photosystem I (PSI), a protein complex present in the chloroplast, is involved in photosynthesis and generates reactive oxygen species (ROS) in plant. Here, we used the ROS generation property of PSI for cancer therapy. We show that PSI can enter into different kinds of cancer cell like human lung carcinoma (A549) and mouse melanoma (B16F10) cell lines and generate ROS inside the cells. It inhibits the proliferation of cancer cell and causes apoptotic death of cancer cells...
December 20, 2016: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/27984558/the-impact-of-ledipasvir-sofosbuvir-on-hiv-positive-and-hiv-negative-japanese-hemophilia-patients-with-1-4-and-mixed-genotype-hcv
#15
Azusa Nagao, Hideji Hanabusa
INTRODUCTION: About 80% of patients with hemophilia who received non-heated coagulation factor concentrates in the early 1980s were infected with hepatitis C virus (HCV), and about 40% of them were infected with human immunodeficiency virus (HIV). AIM: We evaluated the efficacy and safety of administering ledipasvir (LDV)/sofosbuvir (SOF) to Japanese hemophilia patients. METHODS: Forty-three hemophilia patients with genotype 1 or 4 HCV were treated with LDV/SOF for 12 weeks...
December 7, 2016: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27974712/outcome-of-combination-therapy-with-sofosbuvir-and-ledipasvir-for-chronic-type-c-liver-disease
#16
Satoru Hagiwara, Naoshi Nishida, Tomohiro Watanabe, Toshiharu Sakurai, Hiroshi Ida, Yasunori Minami, Masahiro Takita, Tomohiro Minami, Mina Iwanishi, Hirokazu Chishina, Kazuomi Ueshima, Yoriaki Komeda, Tadaaki Arizumi, Masatoshi Kudo
INTRODUCTION: Recently, the treatment of chronic hepatitis C has markedly advanced. A phase III clinical study of combination therapy with sofosbuvir (SOF) and ledipasvir (LDV) was conducted in Japan, and the additive therapeutic effects were reported. In this study, we report the results of treatment in our hospital. METHODS: Of 147 patients with chronic type C liver disease who had consulted our hospital since September 2015 and received SOF/LDV therapy, in 91 subjects a sustained virological response of 12 weeks (SVR12) could be evaluated...
December 15, 2016: Oncology
https://www.readbyqxmd.com/read/27965915/mixed-fibronectin-derived-peptides-conjugated-to-a-chitosan-matrix-effectively-promotes-biological-activities-through-integrins-%C3%AE-4%C3%AE-1-%C3%AE-5%C3%AE-1-%C3%AE-v%C3%AE-3-and-syndecan
#17
Kentaro Hozumi, Kyotaro Nakamura, Haruna Hori, Mari Miyagi, Rika Nagao, Keiko Takasaki, Fumihiko Katagiri, Yamato Kikkawa, Motoyoshi Nomizu
Mimicking the biological function of the extracellular matrix is an approach to developing cell adhesive biomaterials. The RGD peptide, derived from fibronectin (Fn), mainly binds to integrin αvβ3 and has been widely used as a cell adhesive peptide on various biomaterials. However, cell adhesion to Fn is thought to be mediated by several integrin subtypes and syndecans. In this study, we synthesized an RGD-containing peptide (FIB1) and four integrin α4β1-binding-related motif-containing peptides (LDV, IDAPS, KLDAPT, and PRARI) and constructed peptide-chitosan matrices...
2016: BioResearch Open Access
https://www.readbyqxmd.com/read/27943544/treatment-of-hepatitis-c-virus-recurrence-after-transplantation-with-sofosbuvir-ledipasvir-the-role-of-ribavirin
#18
Brigitta Globke, Nathanael Raschzok, Eva-Maria Teegen, Johann Pratschke, Eckart Schott, Dennis Eurich
INTRODUCTION: Hepatitis C virus (HCV) recurrence after liver transplantation (LT) used to be a serious problem in the era of interferon-based treatment. Since the introduction of modern directly acting antivirals, treatment has become easier and shorter. According to published data, in the natural course of hepatitis C infection the duration of antiviral treatment with sofosbuvir (SOF) und ledipasvir (LDV) may be shortened to 12 instead of 24 weeks, using ribavirin (RBV) in addition. Furthermore, the question of whether or not RBV is really necessary, in a 12-week SOF/LDV treatment in the post-transplant setting, is still unanswered...
December 10, 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27935168/effectiveness-and-safety-of-sofosbuvir-based-regimens-plus-an-ns5a-inhibitor-for-patients-with-hcv-genotype-3-infection-and-cirrhosis-results-of-a-multicenter-real-life-cohort
#19
S Alonso, M Riveiro-Barciela, I Fernandez, D Rincón, Y Real, S Llerena, F Gea, A Olveira, C Fernandez-Carrillo, B Polo, J A Carrión, A Gómez, M J Devesa, C Baliellas, Á Castro, J Ampuero, R Granados, J M Pascasio, A Rubín, J Salmeron, E Badia, J M M Planas, S Lens, J Turnes, J L Montero, M Buti, R Esteban, C M Fernández-Rodríguez
Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014-October 2015). In total, 208 patients were included: 98 (47%) treatment-experienced, 42 (20%) decompensated and 55 (27%) MELD score >10...
December 9, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27934775/real-world-effectiveness-and-predictors-of-sustained-virological-response-with-all-oral-therapy-in-21-242-hepatitis-c-genotype-1-patients
#20
Lisa I Backus, Pamela S Belperio, Troy A Shahoumian, Timothy P Loomis, Larry A Mole
BACKGROUND: Predictors of SVR to all-oral hepatitis C virus (HCV) regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir±ribavirin (LDV/SOF±RBV) and ombitasvir/paritaprevir/ritonavir+dasabuvir (OPrD)±RBV in patients treated in routine practice. METHODS: Observational, intent-to-treat cohort of 21,142 genotype 1 patients initiating 8 or 12 weeks of LDV/SOF±RBV or 12 weeks of OPrD±RBV at any Veterans Affairs facility...
December 9, 2016: Antiviral Therapy
keyword
keyword
95665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"